FUSED IMIDAZOLE DERIVATIVE

Publication number: WO2004096806

Publication date:

2004-11-11

Inventor: Applicant: NAKAHIRA HIROYUKI (JP); HOCHIGAI HITOSHI (JP) SUMITOMO PHARMA (JP); NAKAHIRA HIROYUKI

(JP); HOCHIGAI HITOSHI (JP)

Classification:

- International:

A61K31/52; A61K 31/5377; A61P1/00; A61P3/04; A61K31/52; A61K 31/5377; A61P1/00; A61P3/04; A61P13/08; A61P19/02; A61P3/10; A61P29/ 00; A61P31/18; A61P35/04; A61P37/06; A61P43/ 00; C07D473/18; A61K31/519; A 61K31/5376; A61P1/00; A61P3/00; A61P

A61K31/52; A61K31/5377; C07D473/18

Application number: WO2004JP06104 20040427

Priority number(s): JP20030125715 20030430 ; JP20030352423 20031010

Cited documents:

WQ2004018469 WO03104229

WO03024965 WO03004496

Report a data error here

Abstract of WO2004096806

A compound represented by the following formula (I), a prodrug thereof, or a pharmaceutically acceptable sait of either. The compound has high DPP-IV inhibitory activity and has been improved in safety, toxicity, etc. (I) [In the formula, R<1> represents hydrogen, optionally substituted alkyl, etc.; R<2> represents hydrogen, optionally substituted alkyl, optionally substituted alkyl, etc.; R<3> represents hydrogen, optionally substituted alkyl, etc.; and -Y-NH2 represents, e.g., a group represented by the formula (A) (wherein m is 0, 1, or 2; and R<4> is absent or one or two R<4>'s are present, the R<4>'s each independently representing optionally substituted alkyl, etc.).]

Data supplied from the esp@cenet database - Worldwide

(19) 世界知的所有権機関 国際事務局



(43) 国際公開日 2004年11月11日(11.11.2004)

PCT

(10) 国際公開番号 WO 2004/096806 A1

(51) 国際特許分類?: C07D 473/30, 473/18, 473/06, 473/04, 473/22, A61K 31/52, 31/5377, A61P 43/00, 29/00, 19/02, 37/06, 1/00, 3/04, 31/18, 35/04, 13/08, 19/10

(21) 国際出願番号:

PCT/JP2004/006104

(22) 国際出願日:

2004年4月27日(27.04,2004)

(25) 国際出願の言語:

日本語

(26) 国際公開の言語:

特願2003-125715

日本語

(30) 優先権データ:

2003年4月30日(30.04.2003) JР

特願 2003-352423 2003年10月10日(10.10.2003)

(71) 出願人 (米国を除く全ての指定国について): 住友製薬 株式会社 (SUMITOMO PHARMACEUTICALS CO., LTD.) [JP/JP]; 〒5418510 大阪府大阪市中央区道修町 2丁目2-8 Osaka (JP).

(72) 発明者; および

(75) 発明者/出願人 (米国についてのみ): 中平博之

(NAKAHIRA, Hiroyuki) [JP/JP]; 〒5540022 大阪府大 阪市此花区春日出中3丁目1-98 住友製薬株式会社内 Osaka (JP). 方達 均 (HOCHIGAI, Hitoshi) [JP/JP]; 〒 5540022 大阪府大阪市此花区春日出中3丁目1-98 住 友製薬株式会社内 Osaka (JP).

(74) 代理人: 五十部 穣 (ISOBE, Yutaka); 〒5540022 大阪 府大阪市此花区春日出中3丁目1-98 住友製薬株式会 社知的財産部内 Osaka (JP).

(81) 指定国 (表示のない限り、全ての種類の国内保護が 可能): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) 指定国 (表示のない限り、全ての種類の広域保護が可 能): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD,

/続葉有7

(54) Title: FUSED IMIDAZOLE DERIVATIVE

(54) 発明の名称: 縮合イミダゾール誘導体

$$\begin{array}{c|c}
R^{1} & & & \\
R^{2} & & & \\
R^{2} & & & \\
\end{array}$$

$$\begin{array}{c}
N & & \\
N & & \\
N & & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\
N & \\
N & \\
\end{array}$$

$$\begin{array}{c}
N & \\
N & \\$$

$$-N \xrightarrow{\text{(A)}} R^4$$

$$NH_2$$

(57) Abstract: A compound represented by the following formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of either. The compound has high DPP-IV inhibitory activity and has been improved in safety, toxicity, etc. (I) [In the formula, R1 represents hydrogen, optionally substituted R² represents hydrogen, alkyl, etc., optionally substituted alkyl, optionally substituted aryl, etc.; R3 represents hydrogen, optionally substituted aryl, etc.; and -Y-NH2 represents, e.g., a group represented by the formula (A) (wherein m is 0, 1, or 2; and R4 is absent or one or two R4's are present. the R4's each independently representing optionally substituted alkyl, etc.).]

WO 2004/096806 A1